460 related articles for article (PubMed ID: 38384463)
21. Strategies for Increasing Pancreatic Tumor Immunogenicity.
Johnson BA; Yarchoan M; Lee V; Laheru DA; Jaffee EM
Clin Cancer Res; 2017 Apr; 23(7):1656-1669. PubMed ID: 28373364
[TBL] [Abstract][Full Text] [Related]
22. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
[TBL] [Abstract][Full Text] [Related]
23. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Jiang H; Hegde S; Knolhoff BL; Zhu Y; Herndon JM; Meyer MA; Nywening TM; Hawkins WG; Shapiro IM; Weaver DT; Pachter JA; Wang-Gillam A; DeNardo DG
Nat Med; 2016 Aug; 22(8):851-60. PubMed ID: 27376576
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies.
Haqq J; Howells LM; Garcea G; Metcalfe MS; Steward WP; Dennison AR
Eur J Cancer; 2014 Oct; 50(15):2570-82. PubMed ID: 25091797
[TBL] [Abstract][Full Text] [Related]
25. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
26. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment.
Garcia Garcia CJ; Huang Y; Fuentes NR; Turner MC; Monberg ME; Lin D; Nguyen ND; Fujimoto TN; Zhao J; Lee JJ; Bernard V; Yu M; Delahoussaye AM; Jimenez Sacarello I; Caggiano EG; Phan JL; Deorukhkar A; Molkentine JM; Saur D; Maitra A; Taniguchi CM
Gastroenterology; 2022 Jun; 162(7):2018-2031. PubMed ID: 35216965
[TBL] [Abstract][Full Text] [Related]
27. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies.
Senturk ZN; Akdag I; Deniz B; Sayi-Yazgan A
Front Immunol; 2023; 14():1152551. PubMed ID: 37033931
[TBL] [Abstract][Full Text] [Related]
29. Apoptosis in the Pancreatic Cancer Tumor Microenvironment-The Double-Edged Sword of Cancer-Associated Fibroblasts.
Pfeifer E; Burchell JM; Dazzi F; Sarker D; Beatson R
Cells; 2021 Jul; 10(7):. PubMed ID: 34359823
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
[TBL] [Abstract][Full Text] [Related]
31. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
[TBL] [Abstract][Full Text] [Related]
32. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
Liu H; Shi Y; Qian F
Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
[TBL] [Abstract][Full Text] [Related]
33. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
[TBL] [Abstract][Full Text] [Related]
34. Activation of STING in the pancreatic tumor microenvironment: A novel therapeutic opportunity.
Chamma H; Vila IK; Taffoni C; Turtoi A; Laguette N
Cancer Lett; 2022 Jul; 538():215694. PubMed ID: 35489447
[TBL] [Abstract][Full Text] [Related]
35. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer.
Yu Y; Schuck K; Friess H; Kong B
Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383
[TBL] [Abstract][Full Text] [Related]
36. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma.
Liu X; Tang R; Xu J; Tan Z; Liang C; Meng Q; Lei Y; Hua J; Zhang Y; Liu J; Zhang B; Wang W; Yu X; Shi S
Gut; 2023 Nov; 72(12):2329-2343. PubMed ID: 37541772
[TBL] [Abstract][Full Text] [Related]
37. Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma.
Gautam SK; Batra SK; Jain M
Mol Cancer; 2023 Jul; 22(1):118. PubMed ID: 37488598
[TBL] [Abstract][Full Text] [Related]
38. Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours.
Huang HC; Sung YC; Li CP; Wan D; Chao PH; Tseng YT; Liao BW; Cheng HT; Hsu FF; Huang CC; Chen YT; Liao YH; Hsieh HT; Shih YC; Liu IJ; Wu HC; Lu TT; Wang J; Chen Y
Gut; 2022 Sep; 71(9):1843-1855. PubMed ID: 34921062
[TBL] [Abstract][Full Text] [Related]
39. Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma.
Tang D; Wang D; Yuan Z; Xue X; Zhang Y; An Y; Chen J; Tu M; Lu Z; Wei J; Jiang K; Miao Y
Int J Cancer; 2013 Mar; 132(5):993-1003. PubMed ID: 22777597
[TBL] [Abstract][Full Text] [Related]
40. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
